TransCode Therapeutics Secures NIH Grant for Cancer Trials
![TransCode Therapeutics Secures NIH Grant for Cancer Trials](https://investorshangout.com/images/blog/ihnews-TransCode%20Therapeutics%20Secures%20NIH%20Grant%20for%20Cancer%20Trials.jpg)
TransCode Therapeutics Secures $2 Million Grant from NIH
BOSTON — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an innovative RNA oncology company dedicated to improving cancer treatments, has received a significant boost with a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This funding will facilitate the clinical evaluation of TTX-MC138, the company's lead therapeutic candidate aimed at fighting advanced solid tumors. TransCode has activated three clinical trial sites to begin a Phase I/II trial specifically designed to assess the safety of TTX-MC138.
Clinical Trial Details and Goals
The ongoing clinical trial represents a critical step for TransCode as it seeks to gather essential data regarding the safety profile of TTX-MC138. Although the trial will not primarily focus on the treatment's efficacy, there is an opportunity for early indicators of clinical activity in patients who have metastatic cancer. This kind of grant funding is expected to be distributed over a two-year period, underscoring the NIH's commitment to supporting groundbreaking research in oncology.
Insights from Leadership
Dr. Zdravka Medarova, the Chief Scientific Officer of TransCode, expressed her gratitude for this recognition from the NIH. "We are honored that the NIH acknowledges our mission to advance therapies targeted at metastatic cancer," she stated. Dr. Medarova highlighted the rigorous evaluation process grants undergo, suggesting that this achievement speaks volumes about the potential and innovation contained within the TTX-MC138 clinical development program.
About TTX-MC138 and Its Innovations
TTX-MC138 stands out as a groundbreaking therapeutic candidate that addresses the specific challenges of treating metastatic disease. By concentrating efforts on tumors that overexpress microRNA-10b, a known marker of metastasis, TransCode hopes to provide a new hope for patients battling these aggressive cancer types. The strategy behind TTX-MC138 incorporates TransCode's advanced TTX nanoparticle delivery platform, designed to enhance the effectiveness of RNA therapeutics.
Commitment to Advanced Cancer Therapies
TransCode Therapeutics is not only committed to the development of TTX-MC138 but is also actively working on a portfolio of first-in-class RNA therapeutic candidates. These innovative solutions aim to tackle the complexities of RNA delivery and expand therapeutic reach across various types of cancer. The research and development conducted by TransCode reflects its unwavering dedication to reshaping cancer treatment paradigms.
Frequently Asked Questions
What is the purpose of the NIH grant awarded to TransCode?
The NIH grant will support the clinical evaluation of TTX-MC138, focusing on its safety in treating metastatic cancer.
How will the clinical trial design benefit TransCode?
The trial is structured to generate crucial safety data and may offer early signs of clinical activity despite not being focused on efficacy.
Who is leading the research at TransCode Therapeutics?
Dr. Zdravka Medarova serves as the Chief Scientific Officer, overseeing the development of TTX-MC138.
What is TTX-MC138 designed to treat?
TTX-MC138 is developed to treat advanced solid tumors that have an overexpression of microRNA-10b.
What sets TTX-MC138 apart from other treatments?
TTX-MC138 represents a first-in-class therapy targeting metastatic disease, utilizing an innovative RNA nanoparticle delivery system.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Top Financial Stocks to Consider for High Dividend Returns
- Verizon's Bold Move: Acquiring Frontier for Growth
- Understanding Short Interest Trends for Healthpeak Properties
- PCB Financial Expands Deadline for Election Form Submissions
- Transforming Compliance: Zanko ComplianceAssist by Spring Labs
- Insights on AUGA Group's Financial Performance for 2024
- Shell plc Launches Comprehensive Exchange Offers for USD Notes
- Innovations for Women's Health: A Coalition for Change
- Actuate Therapeutics to Showcase Innovations at Key Conference
- Blenders Eyewear Unveils Special Sunglasses for SDSU Players
Recent Articles
- Discover AutoZone's Recent Power Inflow Impact on Stocks
- Navigating Market Volatility: Insights on U.S. and India Stocks
- Insights from CNBC's 'Final Trades' Featuring Major Stocks
- Top Oversold Consumer Staples Stocks Worth Considering Now
- Nvidia Stock Faces Challenges Amid Market Volatility
- Top Financial Stocks to Consider for High Dividend Returns
- Verizon's Bold Move: Acquiring Frontier for Growth
- Understanding Enovix's Short Interest Trends and Insights
- Understanding Short Interest Trends for Healthpeak Properties
- Insights into Equinix's Short Interest Trends and Implications
- PCB Financial Expands Deadline for Election Form Submissions
- P2P Group Strengthens Leadership with Expert Advisory Board
- StealthGas Inc. Achieves Record Results in Latest Financials
- Northrop Grumman's Upcoming Presence at Morgan Stanley Event
- Freight Technologies Shows Growth with Notable Product Advancements
- Exploring XHANCE's Impact on Chronic Sinus Issues
- Transforming Compliance: Zanko ComplianceAssist by Spring Labs
- Insights on AUGA Group's Financial Performance for 2024
- ChannelEngine Empowers Brands to Recover Lost Amazon Revenue
- Rivian CEO to Speak at Key Finance Conference
- Discover the Revolutionary Volumizing Tinted Brow Gel from ABH
- Shell plc Launches Comprehensive Exchange Offers for USD Notes
- Revolutionizing Talent Acquisition with AI-Driven Solutions
- Clip Money Inc. Welcomes New Leadership to its Board
- ILGM Unveils Exclusive Seed Collection in Collaboration
- StealthGas Inc. Achieves Record Q2 2024 Results with Growth
- Angel Kids AI Raises $1.1M in Continued Seed Financing
- Innovations for Women's Health: A Coalition for Change
- Republic Services Earns Eighth Year of Great Workplace Honor
- Elevate Your Skincare with HA Intensifier Multi-Glycan
- First Connect and Root Enhance Insurance Agent Experience
- Actuate Therapeutics to Showcase Innovations at Key Conference
- Kait Dinunzio Joins Pyxis Advisory Group as Managing Director
- Blenders Eyewear Unveils Special Sunglasses for SDSU Players
- BDHEA Secures $1.5M Grant to Enhance Health Equity Efforts
- HanaByte's New Role as a Trusted Cloud Consultant
- New Research Highlights Improved Chemotherapy Tolerability
- Phagenesis Welcomes Chad Hoskins as New CEO to Drive Growth
- NetDiligence Launches Innovative Career Pathways Initiative
- EisnerAmper Expands by Welcoming Tighe, Kress & Orr Partners
- BNY's Acquisition of Archer Enhances Wealth Management Services
- US Signal Expands Leadership Team with New Executive Appointments
- S&P 500 Futures Recover Slightly Amid Jobless Claims Report
- Nordstrom's Strategic Shift: Exploring New Horizons
- Tadawul All Share Index Sees Slight Decline Amid Mixed Trades
- Disney Data Leak: Insights into Financial Strategies and Risks
- Blackstone Secures A$5.5 Billion Loan for AirTrunk Purchase
- US Labor Market Data Influences Stock Market Trends
- Analyst Forecasts Indicate Potential Gains for S&P Global
- Verint's Disappointing Earnings Impact Market Dynamics Today